Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Cheryl Herrera"'
Autor:
Matteo D'Antonio, Grace Woodruff, Jason L. Nathanson, Agnieszka D'Antonio-Chronowska, Angelo Arias, Hiroko Matsui, Roy Williams, Cheryl Herrera, Sol M. Reyna, Gene W. Yeo, Lawrence S.B. Goldstein, Athanasia D. Panopoulos, Kelly A. Frazer
Publikováno v:
Stem Cell Reports, Vol 8, Iss 4, Pp 1101-1111 (2017)
Summary: Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) offers the possibility of studying the molecular mechanisms underlying human diseases in cell types difficult to extract from living patients, such as neurons and cardiomy
Externí odkaz:
https://doaj.org/article/d69ba0728ffa406fb5c715d23e40fe06
Autor:
Angelo Arias, Agnieszka D'Antonio-Chronowska, Cheryl Herrera, Jason L. Nathanson, Hiroko Matsui, Grace Woodruff, Matteo D’Antonio, Kelly A. Frazer, Lawrence S.B. Goldstein, Athanasia D. Panopoulos, Gene W. Yeo, Sol M. Reyna, Roy Williams
Publikováno v:
Stem cell reports, vol 8, iss 4
Stem Cell Reports, Vol 8, Iss 4, Pp 1101-1111 (2017)
Stem Cell Reports
Stem Cell Reports, Vol 8, Iss 4, Pp 1101-1111 (2017)
Stem Cell Reports
Summary Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) offers the possibility of studying the molecular mechanisms underlying human diseases in cell types difficult to extract from living patients, such as neurons and cardiomyo
Autor:
Sol M. Reyna, Francesca S. Boscolo, Louise C. Laurent, Anne M. Remes, Sebastiaan van Gorp, Edward H. Koo, Shauna H. Yuan, Lawrence S.B. Goldstein, Michael P. Hefferan, Fred H. Gage, Yangling Mu, Kristopher L. Nazor, Christian T. Carson, Cheryl Herrera, Martin Marsala, Mason A. Israel, Cedric Bardy
Publikováno v:
Nature, vol 482, iss 7384
Nature
Nature, 482(7384), 216-U107. Nature Publishing Group
Nature
Nature, 482(7384), 216-U107. Nature Publishing Group
Our understanding of Alzheimer's disease pathogenesis is currently limited by difficulties in obtaining live neurons from patients and the inability to model the sporadic form of the disease. It may be possible to overcome these challenges by reprogr
Autor:
Daniel A. Williams, Grace Woodruff, Jessica E. Young, Mason A. Israel, Steven D. Edland, Floyd Buen, Shauna H. Yuan, Jonathan Boulanger-Weill, Lawrence S.B. Goldstein, Arra C. Revilla, Cheryl Herrera
Publikováno v:
Cell stem cell. 16(4)
SummaryPredisposition to sporadic Alzheimer’s disease (SAD) involves interactions between a person’s unique combination of genetic variants and the environment. The molecular effect of these variants may be subtle and difficult to analyze with st
Publikováno v:
Molecular Biology of the Cell
An analysis of dendritic and axonal phenotypes of kinesin heavy chain (KHC) loss-of-function clones revealed a role for KHC in maintaining polarity of neurons, as well as ensuring proper axonal outgrowth. Adenomatous polyposis coli 1 was identified a
Autor:
Angels Almenar-Queralt, Rhiannon L. Killian, Lawrence S.B. Goldstein, Cheryl Herrera, Jessica Flippin
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 1, p e29755 (2012)
PLoS ONE, Vol 7, Iss 1, p e29755 (2012)
The etiology of sporadic Alzheimer disease (AD) is largely unknown, although evidence implicates the pathological hallmark molecules amyloid beta (Aβ) and phosphorylated Tau. Work in animal models suggests that altered axonal transport caused by Kin
Autor:
Ge Yang, Kristina Schimmelpfeng, Lawrence S.B. Goldstein, Richard G. Brusch, Sameer B. Shah, Aaron Pilling, Cheryl Herrera, Valeria Cavalli, Marjan Haghnia
Publikováno v:
Molecular biology of the cell. 18(6)
Transport of cellular and neuronal vesicles, organelles, and other particles along microtubules requires the molecular motor protein dynein ( Mallik and Gross, 2004 ). Critical to dynein function is dynactin, a multiprotein complex commonly thought t
Autor:
Rudolph E. Tanzi, Steven L. Wagner, Shannon Waltz, John M. Ringman, Grace Woodruff, Shauna H. Yuan, Joe Ouyang, Cheryl Herrera, Edward H. Koo, Lawrence S.B. Goldstein, Qing Liu, Floyd Sarsoza, Mason A. Israel
Publikováno v:
JAMA Neurology. 71:1481
Although considerable effort has been expended developing drug candidates for Alzheimer disease, none have yet succeeded owing to the lack of efficacy or to safety concerns. One potential shortcoming of current approaches to Alzheimer disease drug di